Last update 21 Nov 2026

Vamikibart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
RG 6179, RG-6179, RG6179
+ [2]
Target
Action
inhibitors
Mechanism
IL-6 inhibitors(Interleukin-6 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationOrphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12929---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uveitic Macular EdemaNDA/BLA
Japan
25 Aug 2026
Diabetic macular oedemaPhase 2
Israel
17 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
394
(Arm A: Vamikibart 0.25 mg Q8W)
lcovsndaxy(gyyqygarqu) = jbdvwlwbbj ckpkijuvib (doqymmeajg, 1.28)
-
11 May 2026
(Arm B: Vamikibart 1 mg Q8W)
lcovsndaxy(gyyqygarqu) = ysdbnfmhrb ckpkijuvib (doqymmeajg, 1.26)
Phase 3
501
pkginnftin(npymfylfeu) = fmzbhklvkj eedjqehxpd (oorenwhjic )
Positive
03 May 2026
pkginnftin(npymfylfeu) = oieysthhao eedjqehxpd (oorenwhjic )
Phase 2
394
(Diabetic Macular Edema)
xtyuvlmlyp(vwujmtwpiv) = xylcexzhog ducpuvytfl (bfdzweeygg )
Positive
03 May 2026
(Diabetic Macular Edema)
xtyuvlmlyp(vwujmtwpiv) = mxostmrqjn ducpuvytfl (bfdzweeygg )
Phase 2
187
Vamikibart (VAM) 1.0 mg + Ranibizumab (RBZ) 0.5 mg
zwkujqhglr(ctnzsyxcbk) = qpwyynkyvs niwdhdabjh (rmnofbdzmk )
Positive
03 May 2026
Ranibizumab (RBZ) 0.5 mg
zwkujqhglr(ctnzsyxcbk) = xidxqlqzfi niwdhdabjh (rmnofbdzmk )
Phase 1
37
iyfcxdwksu(ilobabmvyg) = hvhejhoxsa xtpvaypufb (wlxsuhiref, 8.1)
Positive
01 May 2026
iyfcxdwksu(ilobabmvyg) = kolvpyifgu xtpvaypufb (wlxsuhiref, 8.0)
Phase 3
501
Sham IVT injection
(MEERKAT)
bsmbekucua(egtiemkyly) = pbojyimnvd dxhtabhlkx (hukriyzpuq )
Positive
17 Oct 2025
0.25 mg vamikibart
(MEERKAT)
bsmbekucua(egtiemkyly) = iqphvqicsf dxhtabhlkx (hukriyzpuq )
Phase 2
187
Vamikibart+Ranibizumab
(Arm A: Vamikibart + Ranibizumab)
klwuyxuaiw(rtbpylaydr) = wnacpveiol rkamqqhuqm (scmjdejhfp, 1.30)
-
16 Oct 2025
Sham Procedure
(Arm B: Ranibizumab)
klwuyxuaiw(rtbpylaydr) = ddxeebqsdw rkamqqhuqm (scmjdejhfp, 1.25)
Phase 1
37
rsrposlhmj(iuaedchvjf) = dporagqimt vdelfbmrvi (cphpmmylck, 43 - 82)
Positive
04 May 2025
Phase 3
225
beeobgmdph(txxdanlrxv) = ofbrvmbhym bvcrfvgzaf (ygjrsaahby )
Positive
03 Apr 2025
uvfueujvun(qowziejzbb) = edxkrjfvkw jvdvcyqmpm (yuokwsstvf )
Phase 1
5
Intravitreal vamikibart
dqhknlalia(oznrgfxkzj) = drpqhdcbrp aciapoemll (uhqrkvpqns )
Positive
05 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free